MAR-PANTOPRAZOLE 40 MG
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 40 MG · DIN 02416565 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-PANTOPRAZOLE?
MAR-PANTOPRAZOLE 40 MG contains PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02416565, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Jul-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-PANTOPRAZOLE used for?
Treatment of conditions requiring gastric acid reduction: duodenal ulcer, gastric ulcer, reflux esophagitis, GERD, NSAID-induced lesion prevention, and H. pylori eradication.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02416565 |
|---|---|
| Brand name | MAR-PANTOPRAZOLE |
| Generic / active ingredient | PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) : 40 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 40 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BC02 PANTOPRAZOLE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Jul-2014 |
| Original market date | 2013-12-03 00:00:00 |
How is it administered?
40 mg once daily for most indications (duodenal/gastric ulcer, GERD, reflux esophagitis). 20 mg once daily for NSAID lesion prevention. Swallow whole; do not chew or crush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General standard for tablets, though specific section 11 text was truncated in snippet).
How is it supplied?
20 mg: Bottles of 100. 40 mg: Bottles of 100 and 500; blister packs of 3x10s.
Contraindications
Hypersensitivity to pantoprazole, substituted benzimidazoles, or any ingredient. Co-administration with rilpivirine is contraindicated.
Warnings and precautions
Risk of Clostridium difficile-associated diarrhea, hypomagnesemia, bone fracture (long-term/high-dose), Vitamin B12 deficiency, and severe cutaneous adverse reactions (SCARs).
Is PANTOPRAZOLE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SIVEM PHARMACEUTICALS ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BC02 PANTOPRAZOLE. 39 of 98 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PANTOPRAZOLE SODIUM | 40 MG | TABLET (DELAYED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02481588 |
| APO-PANTOPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02292912 |
| APO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02292920 |
| AURO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | AURO PHARMA INC | MARKETED | DIN 02415208 |
| BIO-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | BIOMED PHARMA | MARKETED | DIN 02445867 |
| JAMP PANTOPRAZOLE SODIUM | 20 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02392615 |
| JAMP PANTOPRAZOLE SODIUM | 40 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02392623 |
| JAMP-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02357054 |
| M-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | MANTRA PHARMA INC | MARKETED | DIN 02467372 |
| MINT-PANTOPRAZOLE | 40 MG | TABLET (DELAYED-RELEASE) | MINT PHARMACEUTICALS INC | MARKETED | DIN 02417448 |
Who else supplies PANTOPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PANTOPRAZOLE appears in 1645 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.